Clinical Trial Results:
An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing a Pediatric Appropriate Formulation to a 10 Milligram Commercial Atorvastatin Calcium Tablet Formulation in Healthy Subjects
Summary
|
|
EudraCT number |
2012-000728-17 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
01 Feb 2009
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 May 2016
|
First version publication date |
29 Jul 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
A2581174
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00777517 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pfizer Inc.
|
||
Sponsor organisation address |
235 E 42nd Street, New York, United States, NY 10017
|
||
Public contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800 7181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Scientific contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800 7181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000073-PIP01-07 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
10 Jul 2009
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Feb 2009
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Feb 2009
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To determine whether two 5 milligram (mg) tablets of a new atorvastatin calcium chewable tablet formulation were bioequivalent to one 10 mg commercial atorvastatin calcium tablet formulation (Lipitor).
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Nov 2008
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Singapore: 76
|
||
Worldwide total number of subjects |
76
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
76
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Total 76 subjects were enrolled in a single center of Singapore. Study started from 12 November 2008 and completed on 01 February 2009. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
First Intervention Period
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
New Atorvastatin Then Commercial Atorvastatin | ||||||||||||||||||
Arm description |
Two chewable tablets of new atorvastatin were administered on Day 1 of first intervention period of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
New Atorvastatin
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Chewable tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Subjects received two 5 mg (10 mg) new atorvastatin calcium chewable tablets.
|
||||||||||||||||||
Arm title
|
Commercial Atorvastatin Then New Atorvastatin | ||||||||||||||||||
Arm description |
A single tablet of commercial atorvastatin was administered on Day 1 of first intervention period of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Commercial Atorvastatin
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Subjects received a single commercial atorvastatin calcium tablet of 10 mg .
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Washout Period (At Least 14 Days)
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
New Atorvastatin Then Commercial Atorvastatin | ||||||||||||||||||
Arm description |
Two new atorvastatin calcium chewable tablets administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
Arm title
|
Commercial Atorvastatin Then New Atorvastatin | ||||||||||||||||||
Arm description |
Single commercial atorvastatin calcium tablet administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||
|
|||||||||||||||||||
Period 3
|
|||||||||||||||||||
Period 3 title |
Second Intervention Period
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
New Atorvastatin Then Commercial Atorvastatin | ||||||||||||||||||
Arm description |
Subjects who received new atorvastatin in the first intervention period, were administered with a single tablet of commercial atorvastatin on Day 1 of second intervention period of 5 days. | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Commercial Atorvastatin
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Subjects received a single commercial atorvastatin calcium tablet of 10 mg .
|
||||||||||||||||||
Arm title
|
Commercial Atorvastatin Then New Atorvastatin | ||||||||||||||||||
Arm description |
Subjects who received commercial atorvastatin in the first intervention period, were administered with two chewable tablets of new atorvastatin on Day 1 of second intervention period of 5 days. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
New Atorvastatin
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Chewable tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Subjects received two 5 mg new atorvastatin calcium chewable tablets.
|
||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
First Intervention Period
|
|||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
New Atorvastatin Then Commercial Atorvastatin
|
||
Reporting group description |
Two chewable tablets of new atorvastatin were administered on Day 1 of first intervention period of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||
Reporting group title |
Commercial Atorvastatin Then New Atorvastatin
|
||
Reporting group description |
A single tablet of commercial atorvastatin was administered on Day 1 of first intervention period of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||
Reporting group title |
New Atorvastatin Then Commercial Atorvastatin
|
||
Reporting group description |
Two new atorvastatin calcium chewable tablets administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||
Reporting group title |
Commercial Atorvastatin Then New Atorvastatin
|
||
Reporting group description |
Single commercial atorvastatin calcium tablet administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods. | ||
Reporting group title |
New Atorvastatin Then Commercial Atorvastatin
|
||
Reporting group description |
Subjects who received new atorvastatin in the first intervention period, were administered with a single tablet of commercial atorvastatin on Day 1 of second intervention period of 5 days. | ||
Reporting group title |
Commercial Atorvastatin Then New Atorvastatin
|
||
Reporting group description |
Subjects who received commercial atorvastatin in the first intervention period, were administered with two chewable tablets of new atorvastatin on Day 1 of second intervention period of 5 days. | ||
Subject analysis set title |
New Atorvastatin
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Two new atorvastatin calcium chewable tablets of 5 mg administered in either first or second intervention period.
|
||
Subject analysis set title |
Commercial Atorvastatin
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
A single commercial atorvastatin tablet of 10 mg administered in either first or second intervention period.
|
|
|||||||||||||
End point title |
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Atorvastatin | ||||||||||||
End point description |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
AUClast | ||||||||||||
Statistical analysis description |
Natural log transformed AUClast of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.
|
||||||||||||
Comparison groups |
New Atorvastatin v Commercial Atorvastatin
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
Method |
|||||||||||||
Parameter type |
Percent geometric mean (GM) ratio | ||||||||||||
Point estimate |
103.48
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
99.34 | ||||||||||||
upper limit |
107.79 |
|
|||||||||||||
End point title |
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Atorvastatin | ||||||||||||
End point description |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical analysis for AUCinf | ||||||||||||
Statistical analysis description |
Natural log transformed AUCinf of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.
|
||||||||||||
Comparison groups |
New Atorvastatin v Commercial Atorvastatin
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
Method |
|||||||||||||
Parameter type |
Percent GM ratio | ||||||||||||
Point estimate |
102.91
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
99.02 | ||||||||||||
upper limit |
106.96 |
|
|||||||||||||
End point title |
Maximum Observed Plasma Concentration (Cmax) of Atorvastatin | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Statistical analysis for Cmax | ||||||||||||
Statistical analysis description |
Natural log transformed Cmax of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.
|
||||||||||||
Comparison groups |
New Atorvastatin v Commercial Atorvastatin
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence | ||||||||||||
Method |
|||||||||||||
Parameter type |
Percent GM ratio | ||||||||||||
Point estimate |
108.13
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
98.75 | ||||||||||||
upper limit |
118.4 |
|
|||||||||||||
End point title |
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Plasma Decay Half-Life (t1/2) of Atorvastatin | ||||||||||||
End point description |
Plasma decay half-life was the time measured for the plasma concentration to decreased by one half of its initial concentration. The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area Under the Curve Last (AUClast) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) | ||||||||||||
End point description |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area Under the Plasma Concentration Time Profile From Zero Extrapolated to Infinite Time (AUC inf) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) | ||||||||||||
End point description |
AUC (0 ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Maximum Observed Plasma Concentration (Cmax) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to Reach Maximum Observed Plasma Concentration (Tmax) of ortho hydroxyatorvastatin (o-hydroxyatorvastatin) | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Plasma Decay Half-Life (t1/2) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) | ||||||||||||
End point description |
Plasma decay half-life was the time measured for the plasma concentration to decreased by one half of its initial concentration. The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Notes [1] - Subjects evaluable for this end point. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Area Under the Curve Last (AUClast) of Para-hydroxyatorvastatin (p-hydroxyatorvastatin) | ||||||||||||
End point description |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Notes [2] - Data was not estimable as plasma concentrations were below limit of quantitation for all subjects. [3] - Subjects evaluable for this end point. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Maximum Observed Plasma Concentration (Cmax) of Para- hydroxyatorvastatin (p-hydroxyatorvastatin) | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Notes [4] - Data was not estimable as plasma concentrations were below limit of quantitation for all subjects. [5] - Subjects evaluable for this end point. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Para- hydroxyatorvastatin (p-hydroxyatorvastatin) | ||||||||||||
End point description |
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2
|
||||||||||||
|
|||||||||||||
Notes [6] - Data was not estimable as plasma concentrations were below limit of quantitation for all subjects. [7] - Subjects evaluable for this end point. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) | ||||||||||||
End point description |
An adverse event (AE) was any untoward medical occurrence in a subject who received study vaccine without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Safety analysis set was defined as all subjects who received at least 1 dose of study medication.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Baseline up to 28 days after last dose of study drug
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline up to 28 days after the last administration of the study drug
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
New Atorvastatin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Two new atorvastatin calcium chewable tablets of 5 mg administered in either first or second intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Commercial Atorvastatin
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
A single commercial atorvastatin tablet of 10 mg administered in either first or second intervention period. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |